Compare VSECU & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VSECU | OGN |
|---|---|---|
| Founded | N/A | 1923 |
| Country | United States | United States |
| Employees | 1600 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | N/A | 2020 |
| Metric | VSECU | OGN |
|---|---|---|
| Price | $53.93 | $13.43 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $11.40 |
| AVG Volume (30 Days) | 27.6K | ★ 2.4M |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | ★ 0.60% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.55 |
| Revenue | N/A | ★ $6,216,000,000.00 |
| Revenue This Year | N/A | $0.45 |
| Revenue Next Year | N/A | $1.67 |
| P/E Ratio | ★ N/A | $24.42 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $38.45 | $5.69 |
| 52 Week High | $65.93 | $13.49 |
| Indicator | VSECU | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 69.20 | 72.03 |
| Support Level | $44.69 | $10.05 |
| Resistance Level | $58.94 | $13.46 |
| Average True Range (ATR) | 3.47 | 0.05 |
| MACD | 1.08 | -0.11 |
| Stochastic Oscillator | 81.20 | 57.14 |
VSE Corp is a diversified aftermarket products and services company serving commercial and government markets. The Company's operations include aircraft and airframe parts supply and distribution, and MRO services of aircraft components and engine accessories. The Company operates as a single reportable segment: Aviation, which is a provider of aftermarket parts distribution and MRO services for components and engine accessories supporting commercial, business, and general aviation operators.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.